Our research focuses on
1. new signaling pathways guided by β-arr1, along with endothelin receptors and the collagen receptors such as discoidin domain receptor (DDR) 1 and 2, in driving invasive and metastatic processes, dictating invadosome formation and ECM degradation and the mechanosignaling between cancer cells and cancer-associated fibroblasts (CAFs).

2. how DDR2 contributes to ECM modified supporting tumor growth and reducing immune cell infiltration, affecting immunotherapy's efficacy.

3. the feasibility of co-targeting these pathways for controlling metastatic dissemination in organotypic models and in ovarian cancer xenografts.

4. develop novel immunotherapeutic strategies based on the combination of DDR2 blockade and recombinant bispecific antibodies to improve the safety and clinical efficacy of ovarian cancer immunotherapy.

1. Del Rio D, Masi I, Caprara V, Ottavi F, Albertini Petroni G, Salvati E, Trisciuoglio D, Giannitelli SM, Bagnato A, Mauri E, Spadaro F, Rosanò L. The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential. Cell Death Dis. 2024 May 22;15(5):358. doi: 10.1038/s41419-024-06730-6. PMID: 38777849.
2. Trono P, Ottavi F, Rosano' L. Novel insights into the role of Discoidin domain receptor 2 (DDR2) in cancer progression: a new avenue of therapeutic intervention. Matrix Biol. 2024 Jan;125:31-39. doi: 10.1016/j.matbio.2023.12.003. 
3. Amormino C, Russo E, Tedeschi V, Fiorillo MT, Paiardini A, Spallotta F, Rosanò L, Tuosto L, Kunkl M. Targeting staphylococcal enterotoxin B binding to CD28 as a new strategy for dampening superantigen-mediated intestinal epithelial barrier dysfunctions. Front Immunol. 2024 Mar 6;15:1365074. doi: 10.3389/fimmu.2024.1365074.
4. Terri M, Sandoval P, Bontempi G, Montaldo C, Tomero-Sanz H, de Turris V, Trionfetti F, Pascual-Antón L, Clares-Pedrero I, Battistelli C, Valente S, Zwergel C, Mai A, Rosanò L, Del Pozo MÁ, Sánchez-Álvarez M, Cabañas C, Tripodi M, López-Cabrera M, Strippoli R. HDAC1/2 control mesothelium/ovarian cancer adhesive interactions impacting on Talin-1-α5β1-integrin-mediated actin cytoskeleton and extracellular matrix protein remodeling. J Exp Clin Cancer Res. 2024 Jan 23;43(1):27. doi: 10.1186/s13046-023-02930-8.Masi I, Ottavi F, Del Rio D, Caprara V, Vastarelli C, Giannitelli SM, Fianco G, Mozetic P, Buttarelli M, Ferrandina G, Scambia G, Gallo D, Rainer A, Bagnato A, Spadaro F, Rosanò L. The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer. Cell Death Dis. 2023 Jan 30;14(1):73. doi: 10.1038/s41419-023-05612-7.
5. Díaz Méndez AB, Sacconi A, Tremante E, Lulli V, Caprara V, Rosanò L, Goeman F, Carosi M, Di Giuliani M, Vari G, Silvani A, Pollo B, Garufi C, Ramponi S, Simonetti G, Ciusani E, Mandoj C, Scalera S, Villani V, Po A, Ferretti E, Regazzo G, Rizzo MG. A diagnostic circulating miRNA signature as orchestrator of cell invasion via TKS4/TKS5/EFHD2 modulation in human gliomas. J Exp Clin Cancer Res. 2023 Mar 17;42(1):66. doi: 10.1186/s13046-023-02639-8. 
6. Giannitelli SM, Limiti E, Mozetic P, Pinelli F, Han X, Abbruzzese F, Basoli F, Del Rio D, Scialla S, Rossi F, Trombetta M, Rosanò L, Gigli G, Zhang ZJ, Mauri E, Rainer A. Droplet-based microfluidic synthesis of nanogels for controlled drug delivery: tailoring nanomaterial properties via pneumatically actuated flow-focusing junction. Nanoscale. 2022 Aug 11;14(31):11415-11428. doi: 10.1039/d2nr00827k.
7. Del Rio D, Masi I, Caprara V, Spadaro F, Ottavi F, Strippoli R, Sandoval P, López-Cabrera M, Sainz de la Cuesta R, Bagnato A, Rosanò L. Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin-1/β-arr1 Axis. Front Cell Dev Biol. 2021 Dec 1;9:764375. doi: 10.3389/fcell.2021.764375. PMID: 34926453; PMCID: PMC8672058.
8. Masi I, Caprara V, Spadaro F, Chellini L, Sestito R, Zancla A, Rainer A, Bagnato A, Rosanò L. Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK. Cell Rep. 2021 Mar 2;34(9):108800. doi: 10.1016/j.celrep.2021.108800. PMID: 33657382.
9. Masi I, Caprara V, Bagnato A, Rosanò L. Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation. Front Cell Dev Biol. 2020 Oct 15;8:584181. doi: 10.3389/fcell.2020.584181. PMID: 33178698; PMCID: PMC7593604.
10. Chellini L, Caprara V, Spadaro F, Sestito R, Bagnato A, Rosanò L. Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer. Matrix Biol. 2018 Oct 25. pii: S0945-053X(18)30303-2. doi: 10.1016/j.matbio.2018.10.005. [Epub ahead of print] PubMed PMID: 30367951.   
11. Di Modugno F, Caprara V, Chellini L, Tocci P, Spadaro F, Ferrandina G, Sacconi A, Blandino G, Nisticò P, Bagnato A, Rosanò L. hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process. Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3132-3137.
12. Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Veglione M, Castro VD, Spadaro F, Ferrandina G, Bagnato A, Rosanò L. Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway  in ovarian carcinoma. Oncogene. 2016 Jun 30;35(26):3432-42.
13. Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A. Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 2014 Dec 15;74(24):7453-64.
14. Rosanò L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013 Sep;13(9):637-51. 
15.  Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati  E, Nicotra MR, Natali PG, Bagnato A. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11.

PUBBLICATIONS N. 96

H-index =38  (Scopus)